Compared to anti-PD-L1, anti-PD-1 therapies are more frequently associated with pneumonitis (2.4% vs 0%), rash (12.2% vs 5.5%), vitiligo (4.0% vs 0%), colitis (0.7% vs 0%), hepatitis (0.4% vs 0%), hypothyroidism (5.1% vs 2.2%), hyperthyroidism (1.6% vs 0%), and anaemia (4.8% vs 0.7%) 34. Here, PDCD1 is linked to hyperthyroidism.